Brian O Mahony Shares Amit Nathwani’s Research from BIC 2025 on FVII and FIX Gene Therapies for Hemophilia
Brian O Mahony, CEO of Irish Haemophilia Society, Former President of WFH and EHC, shared on X:
”Nathwani from UCL BIC 2025 on their original FIX Gene Therapy trial.
First PWH now 15 years post. Average 13 years.
Stable expression of 2-5%FIX.ABR decreased from average 14 to 1.5. 7 of 10 off prophylaxis.
Reduction in ABR cumulative with decreased microbleeds and synovial inflammation over time.
2 unrelated malignancies. 1) PWH had liver biopsy at 10 years post- showed stable FIX transgene in liver in approximately 5% of hepatocytes transduced”
”Nathwani BIC 2025 on UCL plans to begin FVII Gene Therapy clinical trial in 2026.
Similar vector design as haemophilia B. cDNA small size at 1.4Kb so fits easily into AAV.Dose low at 6E11 vg/kg.
Eligible- severe FVII grade 3, at least 16 years of age, male or female
Interestingly, looking at cost only reimbursement model supported by foundations in UK and US so should be affordable if development works”
More from BIC 2025 featured in Hemostasis Today.
-
Dec 19, 2025, 06:13Anna Aldehag Reflects on Her 12 Year Leadership in Sweden National Board of Health and Welfare
-
Dec 19, 2025, 05:54Abdul Mannan: APTT Mixing Studies Confuse a Lot of People
-
Dec 18, 2025, 23:14The “Normal” FVIII Level Trap in Females with Haemophilia
-
Dec 18, 2025, 23:11WFH Expands Multidisciplinary Bleeding Disorder Training in Vietnam
-
Dec 18, 2025, 17:13Daria Camilli on EuroBloodNet and EHC Collaboration for Bleeding Disorders
-
Dec 18, 2025, 16:50Marie Cambot on Innovhem’s Quantification of The HbF/HbS Ratio for SCD
-
Dec 18, 2025, 16:26Yogesh Rathod on Hematological Issues and ICU
-
Dec 18, 2025, 16:09Carlos Doti: I’m Reminded Why ASH is Such a Powerful Close to The Year
-
Dec 18, 2025, 15:23Michael Hadley: Well-Timed ACC Statement Just Out in JACC Journals